Skip to content

The research of MRGPRX2 transcripts as a biomarker for clinical drug allergic reactions

The research of MRGPRX2 transcripts as a biomarker for clinical drug allergic reactions

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-DDD-17012993
Enrollment
Unknown
Registered
2017-10-15
Start date
2017-10-11
Completion date
Unknown
Last updated
2017-10-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

allergy

Interventions

Gold Standard:According to the severity of allergic reactions, the clinical manifestations are divided into four levels, as follows: Grade1: Only cutaneous signs, rash and urticaria. Grade2: Cutaneous
cardiovascular signs include tachycardia, hypotension
Respiratory disturbances include difficulty inflating, wheezing and cough. Grade3: Life-threaten
Index test:MRGPRX2(Reverse&#32

Sponsors

Xi'an Jiaotong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients had an operation during the sample period; 2. Aged 20 to 80 years.

Exclusion criteria

Exclusion criteria: 1. Patients whose transcript level of MRGPRX2 is lower than the limit of detection; 2. Woman who is pregnant; 3. Patient suffers with anaphylactoid reaction die in 24 hours; 4. Samples with inadequate information; 5. Samples which take or keep unproperly; 6. Samples been polluted; 7. Samples which fall to be detacted reasonably.

Design outcomes

Primary

MeasureTime frame
Sensitivity;specificity;Positive predictive value;Negative predictive value;

Countries

China

Contacts

Public ContactLangchong He

Xi'an Jiaotong University

helc@mail.xjtu.edu.cn+86 029 82655392

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026